PTCT:NASDAQ
PTC Therapeutics, Inc.
$65.37
arrow_downward
-3.87%(-2.63) 1D
$65.37
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$68.00
High
$68.00
Low
$65.18
Mkt. cap
5.46B
Avg. vol.
874.78K
Volume
3.86M
52-wk high
$90.86
52-wk low
$57.74
EPS
-$0.56
Beta
0.55
Shares outstanding
83.46M
No. of employees
991
Open
$68.00
High
$68.00
Low
$65.18
Mkt. cap
5.46B
Avg. vol.
874.78K
Volume
3.86M
52-wk high
$90.86
52-wk low
$57.74
EPS
-$0.56
Beta
0.55
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
Investing.com
·
11 hours ago
PTC Therapeutics director Schmertzler sells $1.35m shares
MarketBeat
·
17 hours ago
PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares
Kalkine Media
·
18 hours ago
PTC Therapeutics Director Michael Schmertzler Executes 20,000 Share Sale Under 10b5-1 Trading Plan
Stock Titan
·
19 hours ago
PTC Therapeutics (NASDAQ: PTCT) director offloads 20,000 shares under trading plan
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com